Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

Jun Cao1,2, Biyun Wang1,2, Jian Zhang1,2, Zhonghua Tao1,2, Leiping Wang1,2 and Xichun Hu1,2*

1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Background: Pucotenlimab, also called HX008, is a humanized anti-PD-1 antagonist IgG4 mAb. It blocks programmed cell death protein 1 (PD-1), programmed-death ligand 1 (PD-L1), and programmed death ligand-2 (PD-L2). In the CBCSG 006 trial, gemcitabine plus cisplatin (GP) has shown impressive antitumor activity as first-line therapy for metastatic triple-negative breast cancer (mTNBC). The phase 1b study was conducted to assess the safety and preliminary antitumor activity of pucotenlimab when combined with GP in patients with mTNBC in the first-line setting.

Methods: Eligible patients with mTNBC with ≥6 months of DFI (disease-free interval) who have never received antitumor therapy for metastatic disease were screened. Participants received pucotenlimab at 3 mg/kg (d1, q3w) plus gemcitabine at 1,250 mg/m² (d1, 8, q3w) and cisplatin at 75 mg/m² (d1, q3w). Eligible patients received up to six cycles of pucotenlimab along with GP chemotherapy, while pucotenlimab could be maintained until disease progression or unacceptable toxicity occurred or withdrawal of informed consent. This study was registered in China under registration number CTR20191353.

Results: Between July 2019 and March 2020, 31 patients were enrolled in this study. The median age was 50 (range 28–68) years. Among 31 patients who were evaluated, 25 (80.6%) experienced objective response and the other six (19.4%) experienced stable disease (SD). As of 4 August, the median progression-free survival (PFS) was 9.0 months (95% CI, 6.2–9.2). The most common grade 3 or 4 treatment-related adverse events included neutropenia (74.1%), anemia (35.5%), thrombocytopenia (32.3%), hypocalcemia (9.7%),...
hypokalemia (9.7%), and alanine aminotransferase increased (6.5%). There were no treatment-related deaths.

**Conclusion:** Pucotenlimab plus GP demonstrated promising activity and a manageable safety profile in patients with mTNBC in the first-line setting.

**KEYWORDS**
immunotherapy, pucotenlimab, gemcitabine, cisplatin, metastatic triple-negative breast cancer

---

**Introduction**

Triple-negative breast cancer (TNBC) has a poor prognosis compared with other subtypes and accounts for 12–17% of all breast cancers (1). The median overall survival (OS) of patients with mTNBC is poor (8–13 months) (2, 3). It has been acknowledged to be a heterogeneous disease that exhibits significant differences, such as biological behavior, pathological characteristics, and gene expression profiles (4, 5). Several previous studies have investigated the molecular subtyping of TNBC and potential targets in different TNBC subgroups (6, 7). In Fudan University Shanghai Cancer Center (FUSCC), we also did comprehensive research on the genomic and transcriptomic landscape of Chinese TNBC, which is named as FUSCC subtype (8). Chemotherapy is recommended as the main systemic treatment in mTNBC, although with suboptimal efficacy and considerable toxicity. Novel therapy is urgently needed. Immunotherapy has been a popular and promising treatment strategy for a variety of tumors, such as lung cancer, cervical cancer, urothelial carcinoma, and so on. It was reported that PD-L1 and tumor-infiltrating lymphocytes (TILs) showed prognostic value in early TNBC (9–11). A higher percentage of TILs was also supposed to be associated with response to atezolizumab in earlier lines of treatment, particularly in the first-line in mTNBC (12). However, PD-L1/PD-1 antibodies were demonstrated with low response rates when used as single-agent treatment in previous studies (13–15). Chemotherapy can induce tumor antigen release. As a result, it may enhance the antigenicity of cancer cells, upregulate PD-L1 expression level on tumor cells, and increase the number of CD8+ TILs (16, 17). According to the results of the Impassion 130 study (18) and the Keynote 355 study (19), both atezolizumab and pembrolizumab showed promising efficacy for patients with PD-L1 positive mTNBC in the first-line setting. Gemcitabine plus cisplatin (GP) has shown satisfying antitumor activity in CBCSG 006 trial (ClinicalTrials.gov, NCT01287624) (20) and has been recommended as a standard treatment in the first-line setting for mTNBC in various Chinese breast cancer guidelines and German Gynecological Oncology Group (AGO) recommendations (21).

Pucotenlimab is a humanized IgG4 anti-PD-1 monoclonal antibody with an engineered Fc domain that blocks PD-1, PD-L1, and PD-L2 (22). As it uses the IgG4 Fc isotype, it has no antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity, which can avoid killing PD-1-expressing immune cells. Pucotenlimab showed significant inhibition of tumor growth both in vivo and in vitro, which suggests that it is a promising candidate for immunotherapy (22, 23). Based on the pharmacokinetics from a phase I trial, pucotenlimab had an acceptable toxicity profile and 3 mg/kg or 200 mg every 3 weeks is recommended as an optimal dose for further drug development (24).

The phase Ib study was conducted to assess the safety and preliminary antitumor activity of pucotenlimab, along with GP, in Chinese patients with mTNBC in a first-line setting.

**Materials and methods**

**Eligibility criteria**

Eligible patients were ≥18 and ≤70 years of age with histologically confirmed TNBC either from the primary or metastatic tumor, with stage IV disease, and with ≥6 months of DFI and naive to previous systemic treatment for metastatic disease. Triple-negative was defined as <1% staining in the nuclei of ER and PR expression and no overexpression of HER2, which were all judged according to American Society of Clinical Oncology–College of American Pathologists guideline criteria (25, 26). The establishment of ER, PR, and HER2 status was done preferentially with tissue from recurrent or metastatic lesions, but the primary breast cancer tissue was also acceptable when the metastatic biopsy specimen was unavailable for irresistible reasons. Additional key eligibility criteria include Eastern Cooperative Oncology...
Group performance status (ECOG PS) of 0 or 1; at least one measurable lesion assessed by Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) at baseline; adequate organ function and a life expectancy of 3 months or more. Previous adjuvant or neoadjuvant settings were acceptable, but they should be completed at least 6 months before metastatic disease is diagnosed. The main exclusion criteria included symptomatic or unstable CNS metastases; active or history of autoimmune disease; history of interstitial lung disease or pulmonary fibrosis; prior treatment with anti-PD-1/PD-L1, anti-CTLA-4, or other similar agents; and adverse events (AEs) from previous therapy that had not recovered to grade 1 or less according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 5.0).

Study design and treatment

This study was an open-label, single-arm, phase Ib study of pucotenlimab combined with gemcitabine and cisplatin as first-line treatment for patients with mTNBC. Eligible patients received pucotenlimab 3 mg/kg by intravenous infusion on day 1, gemcitabine at 1,250 mg/m² on days 1 and 8, and cisplatin 75 mg/m² on day 1. A maximum of six cycles of GP chemotherapy was given, while HX008 could be maintained until disease progression, unacceptable toxicity occurred, or withdrawn according to the decisions of patients.

The study protocol was approved by the Ethics Committee of FUSCC. The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent before enrollment. The trial is registered in China under registration number CTR 20191353.

Endpoints

The primary endpoint was safety. The secondary endpoints were progression-free survival (PFS, defined as the time from the date of randomization to progression or death from any cause, whichever occurred first), objective response rate (ORR, defined as a best response of complete or partial response from the start of treatment until disease progression or death, in accordance with the RECIST 1.1 criteria), 6-month PFS rate, overall survival (OS, defined as the time from randomization to death from any cause), and pharmacokinetics parameters (not addressed in this article).

All AEs were recorded and followed up from the initiation of treatment to 30 days after the last dose of protocol treatment or the start date of subsequent anti-tumor therapy. AEs were graded according to NCI CTCAE, version 5.0.

Tumor response was assessed by investigators with CT or MRI, using Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) every 6 weeks until week 24, then every 8 weeks until discontinuation or up to 2 years, and then every 12 weeks for 1 year and every 24 weeks for subsequent years. Investigators evaluated tumor response according to immune-related RECIST (iRECIST) to determine whether subsequent treatment should be performed.

Statistical analysis

This phase 1b study was designed to enroll at least 15 evaluable patients. More subjects would be enrolled if there were patients with treatment discontinuation for reasons other than safety. The full analysis set (FAS) is comprised of patients who successfully received at least one dose of pucotenlimab. Safety and efficacy will be statistically analyzed based on the FAS. Safety was analyzed using descriptive statistics. The median PFS and DOR (duration of response) were estimated using the Kaplan–Meier method. Data analyses were conducted using SAS statistical software (version 9.4).

Results

Baseline patient characteristics

From July 2019 to March 2020, 31 patients were enrolled in this study. All patients were evaluable and had received ≥1 dose of pucotenlimab combined with gemcitabine plus cisplatin. Baseline characteristics are listed in Table 1. The median age was 50 (range 28–68) years. Overall, 24 patients were histologically confirmed as triple-negative in the primary tumor tissue and the remaining seven patients in the metastatic tissue. Approximately 81% had visceral metastasis. Most patients had received adjuvant or neoadjuvant chemotherapy and had a disease-free interval (DFI, defined as the interval from the completion of primary breast cancer surgery to the diagnosis of recurrence or metastasis) of ≥1 year.

At the data cutoff (4 August 2021), the median follow-up duration was 18.1 months (range 4.2–21.8), with a median duration of treatment of 8.2 months (range 0.03–20.93). Patients received a median of 12 (range 1–31) cycles of pucotenlimab treatment and a median of 6 (range 2–6) cycles of chemotherapy. A total of 27 patients (87.1%) discontinued study treatment. The main reasons for discontinuation were disease progression (19/27), the decision of investigators (4/27), and the choice of patients (4/27). Four patients (12.9%) were still under treatment.
Safety

All patients (31/31) were reported to have treatment-related adverse events. The most common treatment-related AEs (TRAEs) were leukopenia (100.0%), anemia (100.0%), neutropenia (96.8%), hypomagnesemia (93.5%), fatigue (93.5%), and anorexia (90.3%) (Table 2). Grade ≥3 TRAEs occurred in 23 patients (74.2%). The most frequent grade ≥3 TRAEs were neutropenia (74.1%), anemia (35.5%), thrombocytopenia (32.3%), hypocalcemia (9.7%), hypokalemia (9.7%), and alanine aminotransferase increased (6.5%). Serious adverse events (SAEs) included anemia (6.5%), thrombocytopenia (6.5%), alanine aminotransferase increased (6.5%), neutropenia (3.2%), anorexia (3.2%), fatigue (3.2%), hypokalemia (3.2%), and hypocalcemia (3.2%), occurred in seven (22.6%) patients, and all recovered after best supportive care. Immune-related TRAEs included hypothyroidism (32.3%), skin reactions (25.8%), hyperthyroidism (16.1%), and adrenal insufficiency (3.2%), nearly all of which were grade 1 or 2. Immune-related TRAEs are listed in Table 3.

Only one patient in this study discontinued the treatment because of TRAEs. Approximately 67.7% of patients had TRAEs, TABLE 1 Baseline patient characteristics.

| Age (years) | 50 (28-68) |
|-------------|------------|
| <40         | 8 (26%)    |
| ≥40         | 23 (74%)   |

| ECOG performance status |  |
|-------------------------|--|
| 0                       | 1 (3%) |
| 1                       | 30 (97%) |

| Time between breast surgery and recurrent disease |  |
|---------------------------------------------------|--|
| Primary metastatic                                | 2 (6%) |
| <1 year                                           | 4 (13%) |
| ≥1 year                                           | 25 (81%) |

| Number of metastatic organ sites                  |  |
|---------------------------------------------------|--|
| 1                                                  | 5 (16%) |
| 2                                                  | 9 (29%) |
| ≥3                                                 | 17 (55%) |

| Metastatic sites |  |
|------------------|--|
| Lymph nodes      | 23 (74%) |
| Lung             | 20 (65%) |
| Bone             | 11 (35%) |
| Liver            | 11 (35%) |
| Chest wall or skin | 6 (19%) |
| Contralateral breast | 3 (10%) |
| Spleen           | 1 (3%) |
| Renal            | 1 (3%) |
| Adrenal          | 1 (3%) |
| Brain            | 1 (3%) |
| Visceral disease | 25 (81%) |

| Neoadjuvant or adjuvant chemotherapy |  |
|--------------------------------------|--|
| Anthracycline                        | 27 (87%) |
| Taxane                               | 26 (84%) |
| Anthracyline and taxane              | 25 (81%) |

ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PR, progesterone receptor.

TABLE 2 TRAEs of any grade occurring in ≥10% of patients.

| Any grade (%) | Grade ≥3 (%) |
|---------------|--------------|
| Any TRAE*     | 31 (100.0)   | 23 (74.2)   |
| Treatment-related SAEs | 7 (22.6) | 4 (12.9) |
| TRAEs leading to discontinuation | 1 (3.2) | 1 (3.2) |
| TRAE leading to dose delay or reduction | 21 (67.7) | 12 (38.7) |
| Leukopenia    | 31 (100.0)   | 16 (51.6)   |
| Anemia        | 31 (100.0)   | 11 (35.5)   |
| Neutropenia   | 30 (96.8)    | 23 (74.2)   |
| Hypomagnesemia | 29 (93.5) | 1 (3.2) |
| Fatigue       | 29 (93.5)    | 0            |
| Anorexia      | 28 (90.3)    | 0            |
| Hypertriglyceridemia | 27 (87.1) | 1 (3.2) |
| Thrombocytopenia | 25 (80.7) | 10 (32.3) |
| Alanine Aminotransferase increased | 24 (77.4) | 2 (6.5) |
| Hyponatremia  | 23 (74.2)    | 0            |
| Nausea        | 22 (71.0)    | 0            |
| Aspartate Aminotransferase increased | 22 (71.0) | 1 (3.2) |
| Hypocalcemia  | 20 (64.5)    | 3 (9.7)     |
| Constipation  | 19 (61.3)    | 0            |
| Hypercholesterolemia | 19 (61.3) | 0          |
| Hyperglycemia | 18 (58.1)    | 0            |
| Alopecia      | 18 (58.1)    | 0            |
| Hyperuricemia | 18 (58.1)    | 0            |
| Hypokalemia   | 17 (54.8)    | 3 (9.7)     |
| Hypophosphatemia | 17 (54.8) | 0           |
| Proteinuria   | 14 (45.2)    | 0            |
| Weight loss   | 14 (45.2)    | 0            |
| Vomiting      | 12 (38.7)    | 0            |
| Hypercalcemia | 11 (35.5)    | 0            |
| Creatinine increased | 9 (29.0) | 0          |
| Serum amylase increased | 9 (29.0) | 0       |
| Pain          | 8 (25.8)     | 1 (3.2)     |
| Fever         | 7 (22.6)     | 0            |
| Insomnia      | 7 (22.6)     | 0            |

*TRAE, Treatment-related AEs. All adverse events that occurred in at least 20% of patients are listed.

TABLE 3 Immune-related TRAEs.

| Any grade (%) | Grade ≥3 (%) |
|---------------|--------------|
| Hypothyroidism | 10 (32.3) | 0 |
| Skin Reactions | 8 (25.8) | 1 (3.2) |
| Hyperthyroidism | 5 (16.1) | 0 |
| Adrenal insufficiency | 1 (3.2) | 0 |
| Total          | 7 (22.6) | 1 (3.2) |
leading to delayed use of chemotherapy and/or pucotenlimab. The most common TRAEs causing delay were neutropenia (74.1%), thrombocytopenia (51.6%), anemia (29.3%), hypocalcemia (19.4%), alanine aminotransferase increased (9.7%), hypokalemia (9.7%), and fatigue (9.7%). Twelve patients received a dose reduction of chemotherapy for grade 3/4 thrombocytopenia (4/12), creatinine clearance decreased (3/12), anemia (2/12), alanine aminotransferase increased (2/12), and febrile neutropenia (1/12), which were all mainly considered related to chemotherapy. No patient experienced treatment-related fatal AEs.

Efficacy

The efficacy of all 31 patients was evaluable. Among these, one achieved a complete response (CR), 24 achieved partial response (PR), and six achieved stable disease (SD) as their best responses, respectively (Figure 1), with ORR reaching 80.6% and DCR 100%. At the data cutoff, three patients were still receiving pucotenlimab treatment for continuing responses. The median DOR was 7.0 months (range 1.5–18.8). The median PFS was 9.0 months (95% CI 6.2–9.2) (Figure 2), and the 6-month PFS rate was 72.4% (95% CI 52.29%–85.16%). The median OS was not reached (95% CI 15.5, NE) after a median follow-up of 18.1 months (Table 4).

Discussion

This open-label, single-arm, phase Ib study of pucotenlimab combined with gemcitabine and cisplatin demonstrated a manageable safety profile and promising antitumor efficacy as first-line treatment in Chinese patients with mTNBC. The addition of pucotenlimab was well tolerated and did not increase the incidence and severity of TRAEs, which were generally consistent with those of the GP regimen (20). Our study extended observations with another novel PD-
I antibody, pucotenlimab, combined with a standard first-line chemotherapy regimen widely used in Chinese mTNBC daily practice, thereby providing additional treatment options to this population. Most AEs were grade 1/2. Hematotoxicity, including neutropenia, anemia, and thrombocytopenia, was the most frequently reported, which is supposed to be associated with gemcitabine and/or cisplatin. However, the incidences of any grade of serum electrolyte disturbance, such as hypomagnesemia, hyponatremia, hypocalcemia, hypokalemia, and hypophosphatemia, were higher than those in the CBCSG 006 study. Furthermore, hepatotoxicity, such as alanine aminotransferase increased and/or aspartate aminotransferase increased, was also reported more frequently in this study, which was supposed to be enhanced by pucotenlimab, although almost all of these increased TRAEs were grade 1/2. Immune-related toxicities, including hypothyroidism, skin reactions and hyperthyroidism, were comparable to studies with other anti-PD-1 antibodies with or without chemotherapy in breast cancer (14, 15, 18, 19). Only one patient in this study discontinued the treatment because of TRAEs. Approximately 67.7% of patients had TRAEs leading to delayed use of chemotherapy and pucotenlimab, mainly because of hematotoxicity, which was considered more related to chemotherapy. Twelve patients received a dose reduction of chemotherapy, mainly for thrombocytopenia, creatinine clearance decrease, and anemia, which were all considered related to chemotherapy.

The median PFS in this study was 9.0 months (95% CI 6.2–9.2), regardless of the expression status of PD-L1. Meanwhile, in the KEYNOTE 355 study (19), pembrolizumab combined with chemotherapy significantly improved PFS compared with chemotherapy alone in patients with combined positive score (CPS) ≥10 (9.7 months vs. 5.6 months, p = 0.0012). Chemotherapy allowed in this study included gemcitabine plus carboplatin (GC), single-agent of nab-paclitaxel or paclitaxel, according to the choice of the investigator. The subgroup analysis demonstrated that for patients with CPS ≥10, the PFS was all favored for the pembrolizumab-chemotherapy group regardless of the chemotherapy regimen used, although the longest PFS was 9.9 months from the pembrolizumab-nab-paclitaxel subgroup. In the Impassion 130 study (18), the median PFS for PD-L1-positive patients was 7.5 months with atezolizumab combined with nab-paclitaxel, compared with 5.0 months with nab-paclitaxel alone (p <0.001). It was reported that the proportion of mTNBC with CPS ≥10 was about 38% in the KEYNOTE 355 study (19) and PD-L1 expression on tumor-infiltrating immune cells was ≥1% [VENTANA PD-L1 SP142 immunohistochemical testing (27)] was about 41% in the IMPASSION 130 study (18), which still meant that only a small population would benefit from PD-1 or PD-L1 antibodies. Although there was no control group in this study, it suggested that the pucotenlimab plus GP regimen demonstrated potential efficacy in the first-line therapy in the whole mTNBC population, when compared with response and survival data from other classical trials listed in Table 5.

In a phase 1 study of pucotenlimab (24), PD-L1 expression was detected in 10 tumor samples. As a result, none of the 10 samples were PD-L1 positive. The ORR was 30.0% among these of the Table 4 and Table 5.

### Table 4: Response and survival data (FAS population).

| Response | HX008+GP |
|----------|----------|
| Complete response | 1 (3.2%) |
| Partial response | 24 (77.4%) |
| Stable disease | 6 (19.4%) |
| Progressive disease | 0 |
| Missing data or not assessable | 0 |
| Overall response | 26 (80.6%) |

**Progression-free survival**

- Number of events: 26
- Median progression-free survival, months (95% CI): 9.00 (6.18–9.20)

**Overall survival**

- Number of events: 10
- Median overall survival, months (95% CI): NE (15.54, NE)

### Table 5: Response and survival data from some classical phase III trials in the first-line setting in mTNBC.

| Trial         | Regimen                                 | No. of patients | ORR  | Median PFS (months) | Median OS (months) |
|--------------|-----------------------------------------|----------------|------|--------------------|--------------------|
| CBCSG006 (20)| Gemcitabine + cisplatin                 | 118            | 64%  | 7.73               | 19.37              |
|              | Gemcitabine + paclitaxel                | 118            | 49%  | 6.07               | 18.07              |
| Impassion 130 (18) | Nab-paclitaxel + atezolizumab | 451            | 56.0%| 7.2                | 21                 |
|              | PD-L1 positive                          | 185            | 58.9%| 7.5                | 25                 |
|              | Nab-paclitaxel                          | 451            | 45.9%| 5.5                | 17                 |
| Keynote 355 (19) | Chemotherapy + pembrolizumab | 566            | NA   | 7.5                | NR                 |
|              | Chemotherapy + pembrolizumab CPS>10%    | 136            | NA   | 9.7                | NR                 |
|              | Chemotherapy                            | 211            | NA   | 5.6                | NR                 |
| E2100 (28)   | Paclitaxel + bevacizumab                | 233            | NA   | 8.8                | NR                 |

NA, Not Available; NR, Not Reached.
10 patients, indicating a potential effect of this novel PD-1 antibody in PD-L1-negative patients, although it could not determine whether PD-L1 expression could be a good biomarker for immunotherapy owing to the limited sample size. Future exploratory analyses and large-scale tests may provide us with potential biomarkers for selecting appropriate candidates for immunotherapy.

The ORR in this study was 80.6%, which was much higher than those in both CBCSG 006 and the IMPASSION 130 study. However, the OS has not yet been reached yet at the data cutoff (4 August 2021). Future follow-up and a larger sample size of phase 2 or 3 randomized, controlled studies are needed to identify if improved ORR and PFS could convert to OS benefit in the first-line treatment in mTNBC.

Studies on predictive biomarkers for selecting potential subgroups of immunotherapy are ongoing. PD-L1 expression level, high tumor mutation burden (TMB), and MSI-H have been reported to be potential candidates to predict the efficacy of PD-1/PD-L1 antibodies (29, 30). However, no established predictive biomarkers have been widely accepted in mTNBC to date. Exploratory analysis of tumor samples from this study is in progress.

In conclusion, based on the standard treatment of the GP regimen, pucotenlimab in combination with the GP regimen demonstrated a manageable safety profile with promising antitumor activity as first-line treatment in Chinese patients with mTNBC. No unexpected safety signals are observed. Future studies could include the exploration of predictive markers for the addition of pucotenlimab to standard chemotherapy in the mTNBC population.

Data availability statement

The original contributions presented in the study are included in the article suplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Fudan University Shanghai Cancer Center. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Study design: JC, XH, JZ, and BW. Drafting of the manuscript: JC and XH. Statistical analysis: JC, XH, and ZT. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

This study received funding from the Taizhou Hanzhong Biomedical Co. Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Acknowledgments

The authors sincerely thank all of the patients, families, nurses, and staff members who participated in our study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med (2010) 363:1938–48. doi: 10.1056/NEJMra1001389
2. den Brok WD, Speers CH, Gondara L, Baxter E, Tyllesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat (2017) 161(3):549–56. doi: 10.1007/s10549-016-4080-9
3. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med (2015) 12(2):106–16. doi: 10.7497/jissn.2095-3941.2015.0030
4. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 121:2750–67. doi: 10.1172/JCI45014
5. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 30:1879–87. doi: 10.1200/JCO.2011.38.1010

6. Burstein MD, Tiselcion A, Poage GM, Covington RK, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res (2015) 21:1688–98. doi: 10.1158/1078-0432.CCR-14-0432

7. Liu YR, Jiang YZ, Xu XE, Yu KD, Jin X, Hu X, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple negative breast cancer. Breast Cancer Res (2016) 18:33. doi: 10.1186/s13058-016-0690-8

8. Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptic landscape of triple-negative breast cancers: Subtypes and treatment strategies. Cancer Cell (2019) 35:428–40.e5. doi: 10.1016/j.ccell.2019.02.001

9. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 32(27):2959–66. doi: 10.1200/JCO.2013.55.0491

10. Denkert C, von Minckwitz G, Brase JC, Cai L, Ragaz J, Wang Z-H, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol (2015) 33(9):983–91. doi: 10.1200/JCO.2014.58.1967

11. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev (2014) 23(12):2965–70. doi: 10.1158/1055-9965.EPI-14-0654

12. Emens LA, Cruz C, Eder JP, Braith T, Chung C, Tolangay SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol (2019) 5(1):74–82. doi: 10.1001/jamaoncol.2018.4224

13. Nanda R, Chow LQ, Des I, C, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol (2016) 34(21):2460–7. doi: 10.1200/JCO.2015.64.8931

14. Adams S, Schmid P, Rugo HS, Eder JP, Chung C, Tolany SM, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: phase II trial. J Clin Oncol (2019) 37:2509–18. doi: 10.1200/JCO.2018.77.8735

15. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated PD-L1-positive, metastatic triple-negative breast cancer: cohort b of the phase II KEYNOTE-086 study. Ann Oncol (2019) 30(3):405–11. doi: 10.1093/annonc/mdy518

16. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort b of the phase II KEYNOTE-086 study. Ann Oncol (2019) 30(3):405–11. doi: 10.1093/annonc/mdy518

17. Chen DS, Hellmann I. Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 39(1):1–10. doi: 10.1016/j.immuni.2013.07.012

18. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 70(8):3052–61. doi: 10.1158/0008-5472.CAN-09-3690

19. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet (2020) 396(10263):1817–28. doi: 10.1016/S0140-6736(20)32353-9

20. Hu X-C, Zhang J, Xu B-H, Cai L, Ragaz J, Wang Z-H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (BCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol (2015) 16(4):436–46. doi: 10.1016/S1470-2045(15)70064-1

21. Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: Update 2019. Breast Care (2019) 14:247–55. doi: 10.1159/000585099

22. Zhang J, Huang Y, Xi G, Zhang F. HKX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs (2020) 12(1):724–751. doi: 10.1080/19420862.2020.1724751

23. Song Y, Li N, Li Q, Liang X, Zhang S, Fan Q, et al. HKX008, an anti-PD-1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J Immunother Cancer (2020) 8(2):e001279. doi: 10.1136/jitc-2020-001279

24. Liu R, Li W, Meng Y, Gao S, Zhang I, Hu X, et al. Phase I study of pucotenlimab (HKX008), an anti-PD-1 antibody, for patients with advanced solid tumors. Ther Adv Med Oncol (2021) 13:1758859211020528. doi: 10.1177/1758859211020528

25. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 28:2794–95. doi: 10.1200/JCO.2009.25.6529

26. Wolf AG, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. American society of clinical Oncology/College of American pathologists practice guideline focused update. J Clin Oncol (2018) 36(21):2105–12. doi: 10.1200/JCO.2018.77.8738

27. Vennapusa R, Baker B, Kowanetz M, Boone J, Menali I, Bruey JM, et al. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SPI42) for atezolizumab. Appl Immunohistochem Mol Morphol (2019) 27:92–100. doi: 10.1097/PAI.0000000000000594

28. Miller K, Wang M, Gralow J, Dicke M, Coleleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2020) 382:2509–20. doi: 10.1056/NEJMoa2005096

29. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med (2015) 372:529–30. doi: 10.1056/NEJMoa1505096

30. Ruzvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel J, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 348:124–8. doi: 10.1126/science.aab3348